InsiderTrades

Form 4 for LYEL Lyell Immunopharma, Inc.

Accepted 2026-02-11 00:00:00 ET · period of report 2026-02-09 · accession 0001327111-26-000001 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-02-11 2026-02-09 LYEL Seely Lynn Pres, CEO, Dir A - Grant $0.00 +20.0K 82.2K +32% $0
D 2026-02-11 2026-02-10 LYEL Seely Lynn Pres, CEO, Dir S - Sale $23.12 -438 81.7K -0.5% -$10.1K
D 2026-02-11 2026-02-10 LYEL Seely Lynn Pres, CEO, Dir A - Grant $0.00 +155.0K 155.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-09 A A 20,000 $0.00 82,159 D — — (F1) Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 20,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date.
2 Common Common Stock 2026-02-10 S D 438 $23.12 81,721 D — — (F2) Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
3 Derivative Option (right to buy) 2026-02-10 A A 155,000 $0.00 155,000 D $23.71 · — to 2036-02-09 155,000 Common Stock (F3) Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one forty-eighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.